Greetings, and welcome to the Third Quarter 2024 IDEX Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Wendy Palacios, Vice President of FP&A and Investor Relations. Thank you, Wendy. You may begin.

Good morning, everyone. This is Wendy Palacios, Vice President of FP&A and Investor Relations for IDEX Corporation. Thank you for joining us for our discussion of the IDEX third quarter 2024 financial highlights. Last night, we issued a press release outlining our company's financial and operating performance for the 3 months ending September 30, 2024. The press release, along with the presentation to be used during today's webcast, can be accessed on our investor website at investors.idexcorp.com. Joining me today are Eric Ashleman, our Chief Executive Officer and President; and Abhi Khandelwal, our Senior Vice President, Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. Turning to Slide 2. Please note that during today's call, we will present certain non-GAAP financial measures. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we expect or anticipate will or may occur in the future. These forward-looking statements are subject to the risks and uncertainties. Actual results might differ materially from any forward-looking statements that we make today. We do not assume any obligation to update them. Information regarding these factors that may cause actual results to differ materially from these forward-looking statements is available on our website and in our SEC filings. With that, I'll now turn this call over to our CEO and President, Eric Ashleman.

Thanks, Wendy, and good morning, everyone. I'm on Slide 3. Our IDEX teams drove strong Q3 results in an uncertain environment. Here are the highlights. We delivered nice organic growth supported by excellent margins in our Fluid & Metering Technology and Fire Safety and Diversified Products segments. Our free cash flow across IDEX of $192 million was 33% of adjusted net income. Execution through operational excellence was really strong overall. We're pleased to see orders growth within our Health & Science Technologies segment, and our teams are digging into the Mott acquisition with focus energy as we align around our best long-term growth prospects across all of our recent HST acquisitions. We have some important projects to deliver in Q4 in all segments that set us up well for next year. From the start of Q2 to the end of Q3, we really haven't seen a noticeable change in the macro environment. The recent interest rate drop by the Fed and China's stimulus announcements has yet to create positive ripple effects through improved certainty. An extremely close U.S. November election with polarized outcomes also isn't helping in the near term. Take all of that together, and we continue to see an environment where day-to-day order rates remain stable with an absence of larger long-term project commitments. This dynamic really holds true in the more fragmented industrial markets of FMT. We're encouraged by an increase in quoting activity as we move from summer to fall and we don't see projects moving from delayed to canceled. We'll watch for signs either way as many customers move more formally consider their capital and OpEx deployment within calendar budget cycles. We continue to see strength within our intelligent water markets, and I'll talk more about our focused efforts there on the next slide. Within…

Thanks, Eric. Turning to the consolidated financial results on slide 6. Please note that all comparisons are against the prior year period unless stated otherwise. Also, the acquisition of Mott is reflected in IDEX's consolidated and HST segment financials as of the close of the transaction on September 5. Third quarter orders of $781 million were up approximately 10% on a reported basis and up 8% organically. We saw orders growth across the portfolio with HST seeing 20% organic growth in the quarter, half of which was partially driven by blanket order activity that will ship in 2025. FSDP had low single-digit organic growth while FMT was essentially flat. We did see slight sequential growth in FMT orders. Third quarter sales of $798 million were up 1% reported and flat organically compared to the prior year. We experienced organic growth of 4% in FSDP and 2% in FMT. HST had a 5% organic decline driven by continued headwinds that I will cover in the upcoming slides. Third quarter gross margin was 44.3% and adjusted gross margin was 44.6%, an expansion of 20 basis points and 40 basis points, respectively. Gross margin expansion was driven by strong price/cost, partially offset by higher employee-related costs. Third quarter adjusted EBITDA margin was 26.9%, down 150 basis points. With the acquisition of Mott, our biggest acquisition to date, we had higher than typical M&A spending, which negatively impacted our margins by approximately 40 basis points. We are accelerating the integration of Mott and are excited to see the realization of the expected commercial synergies. We continue to leverage 80/20 across IDEX to deploy resources to growth and reduce complexity. I will discuss the drivers of third quarter adjusted EBITDA on the next slide in a moment. On a GAAP basis, our Q3 effective tax…

Thanks, Abhi. I'm on Slide 12. Look, it's easy to get caught up in the economic uncertainties that play out quarter-to-quarter. It's been a frustrating last couple of years as we've seen the last echoes of the pandemic play out against an uncertain geopolitical environment, an environment made more uncertain globally by the unprecedented number of 2024 national elections. We've managed well throughout this period. We've improved the long-term growth prospects of IDEX significantly through incredibly focused work within a proprietary M&A funnel. We have some outstanding people and technologies at our disposal to develop trusted solutions to our customers' most difficult problems. We're building relative and absolute scale across business units to support advantaged markets like water, which we discussed today, advanced semiconductor wafer fabrication, Life Sciences and Analytical Instrumentation and space and defense. We're rapidly digitizing traditionally analog applications throughout IDEX as we transform everything from customer acquisition and support to core product functionality. And we continue to grow through our jump-off points within Asia Pacific as these developing markets reach economic trigger points to adopt IDEX advanced technologies. We sometimes take our abilities to execute for granted. We shouldn't. 80/20 isn't a tool at IDEX. It's evolved into an intuitive headset. We can size up the critical view quicker than others and swing our best people to our biggest challenges and opportunities without the need for time-wasting decision loops. Finally, we're talking about collaboration across business boundaries to build scale more than we have in the past. And some have asked if this challenge is the notion of a decentralized IDEX. It doesn't. We've built our culture intentionally over the last 15 years to prepare us for this moment. Our teams collaborate and help each other naturally without stifling structure and bureaucracy to win for customers. We live our purpose every day through our commitment to our core values of trust, team, and excellence. Thanks again to our IDEX employees and partners around the world for all that you do to make IDEX a great company. With that, I'll turn it over to the operator for your questions.

Thank you. We'll now be conducting a question-and-answer session. [Operator Instructions] Our first question is from Deane Dray with RBC Capital Markets. Please proceed with your question.

Thank you. Good morn everyone.

Morning Deane.

Hey Deane.

Can we start with the tone of business, the day rates? Eric, you already kind of given us the good news that the small project delays didn't escalate. So, that was good. And you gave us some color on BAND-IT. But just the progression of the quarter and your read on the day rates, that would be a great place to start. Thanks.

Yes. As I said kind of in the opening comments, I mean, they've been stable for a while without really a lot of inflection. So, you don't really see anything different through the summer months month-to-month as it played out in the quarter. A lot of it looks pretty similar to where we were in Q2. And of course, we've got the businesses that are closest to consumption. We track those all the time. They've been steady with a little bit of lift in in them, and we see that playing out the numbers that we posted in kind of our core industrial units here. And so I think good shape on those indicators that the kind of industrial system continues and it's -- we're still making things in plants all across the country, and we're maintaining it. That's kind of what a lot of that indicates. The project and the longer-term commitments, I think that's in about the same place, too. The uncertainty and the overhang of, obviously, the election coming up next week, where that's going to take us, those kind of things, I think it's still sort of out there in the way. We're always looking to see if any of those projects start to suddenly move into a category of either delayed -- or canceled instead of delayed or just not talked about any longer. We don't see that. I actually made a comment about the fact that quoting activity, in fact, is picking up a little bit. which I think is a good sign. And then I'm sure we'll get to it at a certain point, we've got a little bit of revenue ramp here in Q4 and almost all of that is project related with a couple of key things that are in the backlog now. Some of them are underway and near completion and I think are also good signs of confidence of the time that's out ahead of us.

And Deane, just to build on Eric's narrative a little bit. So, if you just kind of think about Q3 and just maybe talking about SMT on the face, you see organic growth of 2%, if you will. But if you kind of take a step back and go a step deeper, within the FMT business, pumps and water grew high single-digit. You saw valves group grow high single-digit on an organic basis, which was offset by ag and energy. So, even within HST, the core industrial franchise was up high single-digit.

That's really helpful and I appreciate all that color. And just as a follow-up, I love the fact that you put the spotlight on your Intelligent Water portfolio. We met with the team, got to visit each one of these businesses at the WEFTEC Trade Show in New Orleans recently. So, if we had to point to one probably the fastest-growing sector in the water infrastructure is this whole Stormwater Management. So it's -- you guys -- it looks like you get some first-mover advantage there. Can you just talk about critical mass for the Intelligent Water group? Do you need to add more capabilities? What kind of is the funnel like? And just kind of where and how does this business grow from here?

Yeah. Well, thanks. We appreciate talking to you and others at that show. And you mentioned a key word. We -- in our commentary about kind of our businesses in that area, we pointed to becoming the collection experts. That's really the work we do here. And that has a lot of focus right there, obviously, through things like Stormwater and significant weather events. That's where you see that play out. And so I think we've got the assets positioned in the right place to really, really focus. And as you saw, they work together. They work together in a way where the hardware and analytics help to give you this predictive insight into not just what's going on in your system in front of you, but what's likely to occur in the future. And I think one of the reasons we're winning is, we think about our end customers, it's certainly operating professionals who are trying to run the system. We have significant customer bases that are specification engineers and project engineers within municipalities and industries. And what they're trying to do is, understand the analytics of the system, the way that kind of the water circuit works, if you will. And then they're trying to put that together to obtain capital project approval. And so at this particular phase of the cycle, the cycle has got more positive funding support with longer duration. Being able to understand your system, so that that you can position yourselves to get funding for your municipality or business is really, really important, and it kind of points right back to the core work that we do. That's sometimes underappreciated and really thinks of kind of day-to-day monitoring, but this very specific engineering kind of partnership that helps people understand their system better, actually allows them to go grab funding that is more available now than it has been. Sorry, you also asked about, yeah, other pieces and things and kind of where we are.

Yeah.

I mean, there's -- Subterra is a good example. That's sort of probably an under-the-radar, underappreciated technology that we very much appreciated. We've been working with that company before. And it really helps kind of complete capabilities for us. There are other things we would like to do here within kind of this ecosystem of collection. And so we continue to work in the funnel. We continue to look at things and we're very much -- it is in 80s for us in terms of an area that we would like to make larger, both organically and inorganically overtime.

Great to hear. Thank you.

Thanks Deane.

Our next question is from Nathan Jones with Stifel. Please proceed with your question.

Good morning, everyone.

Good morning, Nathan.

Good morning.

I'm going to follow-up on Deane's question there. Because at [indiscernible], you could say the Intelligent Water businesses altogether kind of united brands showing customers what the combined businesses capabilities were. I'm just thinking about how you run those businesses and potentially, how you run some of the businesses in HST to collaborate together. And Eric, that was one of your closing comments, is collaboration across the business units without losing the decentralized structure. How do you kind of manage that process with these businesses? Do you need some kind of integration with the commercial organization, cross training for sales? And how do you manage those businesses so that you drive the collaboration that you want to see without actually going and integrating the businesses?

Yeah. It's a great question. And that's a great spot to talk about it. I mean, think of it a little bit as it's kind of -- these areas where we put some scale together, they present themselves as kind of mini versions IDEX. And when you step back from IDEX, I mean, one of the ways that we work it the way that we do is nimbly and agilely as we do. It's a super flat organizational structure. So we have a leader of the water business. And between kind of that leader and leaders of individual pieces of water, I mean, there's not a lot of stacking. So think of this as wide and horizontal more than vertical. That's one of the keys here. And the quality of the people, the quality of the system and operating model allows you to take that span a little bit wider. And so you already got something working for you in terms of being close to the point of impact with all leaders. So that's a key ingredient, doesn't change, it's always been part of IDEX and is as we do this work. But it comes down to strategy. A lot of this -- this is why we work so intensively in terms of building strategy and strategic capabilities and doing it in focused 80s areas of IDEX, so that we would be prepared to understand these worlds and why things need to go together and where they don't. And so in every one of these points, we know the difference between an area where there is collaboration and people are working together because the customer cares about it versus other areas where life goes on in individual pieces and specialized segments, which is -- that's where I think a lot of customers -- or companies get caught. They over-rotate one way or the other. We're actually very comfortable delivering in a hybrid world, because we have ever since I've worked at IDEX. We're just becoming a bit more focused to putting some of the scale to work because the solution set demands it. The problems are harder, they're evolving. They're earlier stages of evolution, so you need more power in the system. So it really does lever everything we've ever thought about in terms of 80-20, everything we do culturally, which celebrates flat organizations and a lack of bureaucracy. And probably the secret sauce for all of it is talent and development that that we do internally to make sure leaders are built in a certain way that they can operate with all of that autonomy.

Thanks a lot. I guess, my follow-up question is going to be around the HST order number. 20% organic growth, I think Abhi said half of that was from blanket orders. Is the kind of right way to think about without the blanket orders, the order number would have been something like about 305, which is kind of an average where it's been settled in over the last few quarters since the bottom in 2023? So it's kind of no change sequentially, still waiting and seeing, not really getting any better and not getting any worse. Or are these blanket orders indicative of some kind of improvement in some of those markets?

Yeah. So Nathan, let me try and answer your question. So if you think about it sequentially from 3Q -- or 2Q to 3Q and look at HST, HST was up about $20 million. I'd say about half of that was blanket order activity that we saw from Q2 to Q3 and the other half was just straight demand between different businesses. And then if you think about year-over-year, HST posted about a $51 million organic change in orders on a year-over-year basis. That's, again the same kind of amount for blanket and half of that was demand. So you do see -- go ahead, Nathan.

I was going to say so you are seeing some -- at least some underlying improvement in the markets there?

Yes, we are. Life sciences continues to be stable if you look at sequential. But there are markets, like we've said again, semicon is not at a point where it's inflecting. But we are seeing improvement even in our semicon markets sequentially.

And then reminder -- yeah, just to finish. I mean, we have half of this segment that kind of is in other high-tech areas that are not in the usual suspects of semiconductor and life science and analytical instrumentation. And those, I mean, they're performing a lot like the industrial businesses that we see elsewhere. So we've got some growth and list there. We've had that from before. I just think, look, at the end of the day, we feel good about the position we see here because we've obviously got a big comp number against the low point last year. But we've seen kind of nice progression away from that and we've just now posted the highest order number for the year and the segment built a little bit of backlog and you have a really good comparison.

Correct.

And some signs of optimism in just the conversations we're having with customers. Doesn't say when the next inflection comes, doesn't really talk about the magnitude of it. But having people leaning in the same direction here, that is one of the signs we wanted to see as we start to move away from just baseline stability.

Awesome. Thanks for taking my questions.

Our next question is from Mike Halloran with Baird. Please proceed with your question.

Hey good morning everyone. So first question kind of ties into a couple of answers that you already had. But maybe talk about, how you're thinking about the sequentials in fourth quarter. I know, Eric, I think you briefly mentioned there was some incremental project activity coming in there. But maybe talk about -- it doesn't seem like there's a change in your day rate, choppy, kind of stable, but choppy month-to-month, week-to-week kind of expectations. And how should we think about that into next year from a backlog order cadencing, et cetera, perspective? In other words, relatively normal sequentials, is that how you're thinking about things in the fourth quarter? Or is that a fair assumption to start next year until we see a change in the backdrop? Kind of any thoughts on how you're thinking about how the next few quarters here play out.

Yes. So let me take the Q3 to Q4 sequential, and I'll let Eric jump in. So if you kind of think about Q3 to Q4 and think about the guide that was laid out, it's really -- there are a few different places where we have projects that are in the backlog that we've done a lot of work on that are supposed to ship in Q4. So first is around ABEL. They ship big pumps in, and that's in the backlog that the teams are working on executing and getting out the door. Second place you see it is in pharma, in our MPT business where there's backlog that's booked that we are working on. It's a pretty late stage that's going to get up in Q4. And then the last I'd tell you is tied to Mott. We have a big energy project that's scheduled to go out at the end of the quarter. That's part of Q4 guide. So if you think about the sequential guide from Q3 to Q4, a decent part of the ramp is tied to a few different projects that I just laid out, and that's how we think about the ramp from Q3 to Q4.

And then, look, past that, I think it's going to depend on what we sort of see play out here in the fourth quarter. I do think this is a period where everybody like us is kind forced to come in and consider their next calendar year, if they're on that cycle, in terms of what bets they're going to make, how they're going to make them. They kind of need to talk to critical suppliers like us as they do it. That would be an interesting source that would inflect it other way. But I think a continuation of stability, that seems reasonable as we go forward. And then it's really a question of what layers and on top of it, what are -- the state of health of commitments and the ability to make them kind of where are we sitting at that point with backlog of other projects, including any that might be there for Mott. We'll layer those in, and then we'll have those up-to-the-minute conversations, see what happened here. Of course, in the election, whether or not that triggered anything. So there's the usual number of suspects that would come in there. But it's been kind of a period of now 2 quarters of kind of base level stability. It at least allows you to then kind of see the pieces that rise above it with pretty good clarity or at least the fact that you need to keep digging for it.

So then let's move beyond kind of that horizon and you get towards the point where there is a recovery in the market. How would you think about the growth algorithm now that you've done an iterative reshaping of the portfolio here? You've centralized some resources or added central resources to support the decentralized model, the revenue synergy piece. Could you maybe help on the growth algorithm and then break it down by what the drivers or components of that growth look like from market to synergies, to outperformance or however else you want to categorize it? A – Eric Ashleman: Look, we now have a portfolio that is increasingly starting to weight itself to more faster-growing markets, all the ones that we've acquired into here in HST. And so that's becoming the biggest segment. It's going to carry more of the load as we go forward in periods like the ones you're describing, certainly somewhere off in the future. And so we would see kind of organic rates. We'd always want to outperform our core market entitlements, but we're moving that entitlement to the north. And so we'd like to start to dial IDEX into a kind of mid-single-digit grower plus as we start to navigate that. We'll continue deploy capital on the bottom line. I would say you put a point or two of inorganic growth on top of it, kind of take us to the higher single-digit range when you put the two together. That should allow a beautiful flow-through because these are high-margin businesses and high-margin differentiated markets. And we're still going to practice 80/20 in productivity. We're going to do a lot of it on the acquisitions that we acquired. And so you get nice double-digit earnings expansion through all of that. So slight uptick on the growth rate -- the core growth rates of IDEX because of what's happened in the portfolio, kind of maintenance of the additive dimension of inorganic, which we've demonstrated over the last three years, we've got a system and a method to do that. And then all of it lifting nicely because it's even more differentiated than before, and we continue to know how execute and practice 80/20 really, really well.

Very clear. Thanks, Eric. A – Eric Ashleman: Thank you.

Our next question is from Vlad Bystricky with Citigroup. Please proceed with your question.

Good morning, guys. Thanks for taking my call this morning. A – Eric Ashleman: Good morning, Vlad.

Hey, Vlad.

So I just wanted to dig in on FMT a bit. Just in terms of your commentary and outlook around energy there, which I think you moved from stable to market softness. So can you just talk a little bit more about the dynamics you're seeing in energy in particular and how you're thinking about whether how much election impact might be having an impact on those end markets? Or anything else that you're seeing as sort of an overhang in those?

Yes. I mean, there's -- first, there's two things here. One, I'd always kind of step back a little bit and remind people of the job we do here. We do a lot of downstream work around custody transfer. So as energy moves around the system, that's kind of where we do a lot of our work. Frankly, a lot of that is driven by things like people building trucks and laying in some infrastructure within that transportation system. We've got some overhang there from a really, really warm winter, that's probably spread over that sector throughout. We got a little bit of an artificial bump here to the downside because this was one of the businesses, you might remember, we had a consolidation -- a large-scale consolidation here a couple of years ago. This is one that if you go back in time about a year ago, we were still processing quite bit of backlog in that business. It was one of the last that we had that were kind of eating backlog that it accumulated. And so we got a bit of a comparison issue, because we're now at very standard IDEX levels of lead time and replenishment. So, there's always going to be a little bit of a calibration issue, particularly on a year-over-year basis. So I'd actually take this energy story and say, it's probably half of it that's us, half of it that is a little bit of the pressure there that you'd see in the market. And then just on the question of go forward, obviously, it's sort of an indirect relationship, but health of the energy sector overall will tend to promote CapEx deployment and all the things that eventually find their way downstream to the places where we do business. So we would prefer to have it rather than not. But to be honest, a really, really cold winter will also help, and that has very little to do with politics.

Okay. That's helpful, Eric. Appreciate it. And then maybe just sticking with FMT. Just in terms of the stability you've seen in sort of the day rate orders, any color or commentary you can give on what you're seeing by geography and whether you're seeing any meaningful differences in domestic versus international trends?

Probably, as you suspect, I mean, North America leading the way. That's been the case now for a while, not just by a little but by a lot. I think reasonable stability in Europe. Not a lot of inflection, it moves around a little bit. It's not the bigger piece for us in this particular part of the business. I mean, we're more North American-centric anyways. And then I would say -- and when you go on the other side of the globe, that is a different story. I mean, almost anything we're doing in India right now is really, really good. I would say, China is -- while that story overall, of course, has some sobering characteristics, we've always been super surgical there. And so, it's probably trailing the pack because of where it is and what it's a part of. But we're more than holding our own, because we just -- we choose to make certain bets in certain places that are honestly they're very small, representative of the entirety of that economy. So if you're going to put them in order, probably I would say India first, but it's a smallest piece of IDEX; North America, strong, and that's driving a lot of it; Europe is stable and lagging a little bit behind. I'd probably put China at the back, but still positive for us.

Okay. Appreciate that. Thanks.

Yes.

Our next question is from Jeff Sprague with Vertical Research Partners. Please proceed with your question.

Hey. Thank you. Good morning, everyone.

Hi, Jeff.

Eric, hi. I want to come back just to the HST orders again and sort of blanket orders starting to come in. Eric, is there anything there in sort of the number of customers, the size of the orders that actually helps kind of firm up a view into 2025? Obviously, there's got to be some normalization going on here. So just your context, right, is maybe apparently the channel inventory liquidations have run their course and maybe we're getting to some sort of normalization here.

I think even though, of course, it's a strong and sharp comparison year-over-year, when you actually dig into kind of each one of the entries, I think they're more generalized in terms of how you would interpolate them all. And you have to kind of add them all up and get some more general conclusions. But they're -- you put them all together, they are still positive. So -- and you cited one there. So the fact that these are laying in and laying in across the life science spectrum, it does tell you something about kind of a point of moving from stability towards something different. Again, the rate of advancement, the rate of inflection, still pretty vague and not really determined yet. I'd hold that up in that particular space. Just listen to comments that our teams are having with customers are the ones that are out there in the public, you hear optimism a little bit more. You hear some people talking about fleet aging and where we are in that side of the cycle, some things around consumables, which often lead the way for instruments at some point. And so there's like a little general pieces. But there is a preponderance of them on the right side the page as opposed to the last as we're kind of thinking of the space. And then if we just track over the history and sort of appreciate it quarter-to-quarter over the last year as it's walked this way, you can kind of see it building. I mean, it's a slow build and it doesn't really say what the slope is going to be at this point yet. But it's important. The inventory dynamic that you talked about, that's out there, too for HST. And reminder again, some of these are not life sciences or semi spaces. There are other ones. But those are areas of OEM-centric businesses and little higher customer concentration, and there have been some areas where those customers have had some inventory that we've been working around. And so the extent there's order patterns like this, it does suggest there too that you're further and further away from that. And then the fact that all of the reporting areas that we have, have got some level of organic health in the order side and it's uniform across the segment. Those are the kind of things again that just -- again, they're sort of rough and generalized, but they're important they're additively on the positive side of the ledger versus not.

Understood. And then maybe just coming back to China. I think your prior comments on China just a moment ago were just on -- related to FMT, I apologize if they weren't. But can you just give us kind of the big picture view on China, how it performed in the quarter? And just any context on total IDEX price in the quarter also would be helpful? Thank you.

Yes. On the first part, they're not far off, FMT versus full company because we have a lot of FMT presence there. Really that's kind of the lead segment with some things that we have in fire as well. And I would say it, put the two together, it's basically the same commentary. It's a tiny piece of a giant geography and it's kind of product line based. And so -- and we kind of move in and out depending on which way the wind is blowing. And so when we think we've got technical advantage, we go a little heavier with something that holds up better. And we generally, all of it stays in at least a positive category in an otherwise maybe not quite as positive story, again, which is still a small piece for the company, Abhi?

Yes. And then on the pricing question that you had, we saw about 2.3% price in the quarter and 100 basis point spread that we talked about as part of the guidance in Q2. So that's where we landed for the quarter.

And that's been holding steady, both on the side of equation, yes.

Yes.

Thank you for that. Have a good day. Appreciate it.

Thank you.

Our next question is from Andrew Buscaglia with BNP Paribas. Please proceed with your question.

Hi. Good morning everyone.

Good morning.

I wanted to ask on HST. You're talking about there's still a pickup in semis. Maybe a few questions there. Just what are the customers saying, is giving you insight into that comment, why we wouldn't see that pick up sooner than midyear next year? And then have you guys discussed the margin differential across those four subsegments within HST? And how would that impact the recovery for margins going from here?

All right. Well, I'll take the first part and let Abhi chime in on the second. I mean I think from a semi perspective again, we do pretty narrow focused work there. We're involved in wafer manufacturing and fabrication and metrology, principally on really, really advanced solutions. That's where almost all of the IDEX pieces that do business do it. And I think really, it's a question of factory utilization. I mean, overall, it's until that hits certain levels and there's a catalyst identifiable that's either taken it there or looks like it's going to take it there in the near term, it just doesn't drive kind of big ticket items at a level yet that takes it up to another level. So there's been a series of pretty public announcements in that regard. I think a lot of people pointing to probably the lack of any singular big catalyst beyond, obviously, the things that are happening in AI, but that really doesn't present itself at this point in massive volume. It's more specialized. And so I think whether it's -- that's some kind of consumer gear or a return to lots of PCs that are more advanced than ever, those are the kind of things I think you'd be looking for to take and push the upper limits of those utilization rates to a point where you want to then get in line for some still pretty long lead time gear. And so given that nobody orders this kind of stuff today for delivery tomorrow, it does allow you to probably see into the future a little bit and make a projection like that. So it doesn't mean again that that's necessarily bad market for us. It's just we're kind of all waiting for the next cycle there. And we really are because we've got just an incredible amount of assets that are now positioned for it.

Yeah. And so I'll take a stab of your margin question. So you kind of just think about where HST is. I mean, on a year-over-year basis, our HST margins were down 40 basis points on organic sales being down 5%, right? So I'd say it's a true testament to the work that our teams have done in rightsizing our businesses, frankly, because if you're down 5% organically and the teams didn't do the work they did to take out costs, you'd see a much higher decline on a year-over-year basis. So kudos to our team for rightsizing the size, coupled with driving productivity, coupled with the price/cost spread that we saw in the segment, right? So as you sit here today and look at a 26.5% EBITDA profile and then moving forward, what does that look like? So we announced the acquisition of Mott. We said it was low 20% EBITDA out of the gates. Then we laid out a very clear plan that demonstrates that we're going to generate 400 to 600 basis points of margin improvement in -- at Mott in the next 12 to 18 months. So when you put it all together, coupled with the organic growth coming back in the future, there's no reason for HST not to be a low 30% EBITDA business.

Okay. Got it. That's helpful. Maybe sticking with margins, your price cost has been good. But I feel like every few years, you guys have to navigate some sort of supply chain calamity. And with the election coming up, tariffs are now back in the news. So can you remind us like where you are with your positioning if indeed tariffs come back into the picture and how you're getting ready for that?

Well, I mean, look, I think whether it's supply chain pressure that we experienced in the pandemic or it's an item like that, thinking about supply chain resilient, every company should be and we are we're doing that, too. I will remind people, I mean, as we saw this to our advantage in the pandemic, probably would be an advantage in this environment as well. We're much more localized in terms of ideating and orders placed within the same geography where we actually produce and sell. It doesn't mean there aren't cross-border shipments on the supply and input side. There are at certain levels and certain kind of base level commodities. But we do an awful lot of work within country. So as we think of tackling it, and we're, of course, running scenarios and talking about critical inputs like anybody else, we are appreciative that kind of we built the company around a model that tends to be more localized anyways.

That’s helpful. Thank you.

Thank you. Our next question is from Brett Linzey with Mizuho. Please proceed with your question.

Hey, good morning, all. I wanted to come back to the EBITDA bridge and specifically the resource investment/discretionary, that $12 million. Fairly big step-up sequentially versus Q1. I was hoping you could just unbundle those. Is the resource investment offset by lower discretionary? Or is this discretionary going up too? And then if you could maybe speak to some of those targeted investments and the paybacks.

Yes, let me take the bridge item first. So if you look at the bridge that we put out there on a year-over-year basis, you're seeing a $12 million headwind tied to the question you're asking. So I'd say, a-third of that is tied to higher M&A spend on a year-over-year basis given the fact that we just did our largest transaction with Mott. So that's about a-third of it. The other third is tied to stock comps and the timing of stock comp last year and the tailwind that we saw compared to this year. And then there is some discretionary spend in here tied to customer-facing T&E and the investments that we are making tied to growth initiatives on a year-over-year basis.

Okay. Appreciate that. And then maybe just shifting back to Mott. So it sounds like you're running ahead there. Good integration progress. Should we think about the 2026 accretion target or expectation getting pulled forward based on this fast start? And does that change your thinking at all?

Well, look, we're early days. We're six weeks in the acquisition. We're working the plans, partnering with the local teams. Our teams and the Mott teams are partnering together and laying out a plan over the next 12 months. So it's early days so it's hard to pinpoint to what 2025 versus 2026 is going to do.

I think part of what we want to convey here is that you always -- you're going to get a certain business and meet it, and then you pass the line, you close it. And of course, the reality is there. This reality is every bit as good as what we thought coming in.

Yeah.

And the fact that we were able to integrate some teams as fast as we are, it's an 80s acquisition for us that we're all playing in. And we see as many possibilities do. It's just a real testament. That's the early read, the early excitement, there's still an awful lot of work to do. The world's got to play out. But at least want to make sure we got that out in front of you that at this point, couldn't be happier with what we acquired.

Appreciate the details. Best of luck.

Thank you.

Our next question is from Joe Giordano with TD Cowen. Please proceed with your question.

Hey, good morning, guys. I wanted to touch on the other -- some of the other more recent M&A. So for EA, you guys lowered your expectations last quarter. Just curious, how that's tracking. And then also curious on Muon just given the semi push-outs you've talked about and one of your large customers gave some disappointing orders. So just curious what the latest is on those two businesses?

I'm sorry. Can you talk about what EA means? I'm not sure I followed you. Apologies.

Sorry, sorry. Just focus on Muon. That was my mistake there. Just Muon, given like the weakness in orders at one of your large customers?

Yeah. I mean, look, that's a piece of that business. It's not -- by no means is it all of it or even the majority of it. So -- and even there, I mean, we're -- look, that business is doing -- a portion of it is doing some pretty advanced work that's actually well ahead of machines that are being delivered today. So there's not a one-for-one kind of corollary. So there's a few things there that help out on that side of it. And ultimately, at the end, long cycle, super well positioned. It's got some presence in med tech markets that are doing well because it's exiting some inventory positions. It's got another one that's actually in a very different adjacency as well. So it's not an entirely semi-driven business that is a decent component of it, but it's well positioned and at times a little different than you might suspect in terms of the production cycle. And the other two components, I think, pretty good and holding up. And it is a piece that we're now considering with other Applied Material Science Business technology businesses we have in terms of how all of it works together, including Mott. So we'll be doing some of that work and in some ways, kind of rescaling, recasting all of it together.

Interesting. Okay. And then just curious on the sequential growth in HST. You said half of it was -- roughly half of it was like actual demand. Just curious on the Life Science side. Are we talking more like bioprocessing? Or is it more lab? Just kind of which cohort of customers is really driving that?

Well, for us, it kind of almost has to be in the Analytical Instrumentation kind of course, space just because of our presence. We're not as pronounced in the bio areas.

Perfect. Thanks, guys.

Thank you

Our next question is from Rob Wertheimer with Melius Research. Please proceed with your question. Q – Rob Wertheimer: I know it's late in the call, but Eric, I was listening to your prepared remarks and the conversion of analog processes and tools to digital is something you touched on before. I don't know if your comments were slightly more broad this time. And I'm wondering if you had any further expansion on how you're evolving -- how you guys operate on the team. Thank you.

Yes. Look, it's a team that years ago was kind of harder for us to imagine across all of the smaller pieces of IDEX. But as we started to assemble scale more purposefully, actually this is one of the areas that we're applying it. And so I'll give you a couple of examples that kind of rise to the next level. Doing a lot of work on the front end of a lot of these outstanding FMT franchises, which are more fragmented, more industrial in nature, but the nature of the interactions between ourselves and end customers is more digital than ever. And as a leader in those spaces, I mean, the market is looking for us to kind of lead the way of how this work is going to be done, how does knowledge transfer happen. If somebody calls in and the looking for information, how many people has to manually intervene there versus some automated things that we can do? So we've got -- we've had for a while now, but we're starting to scale it more with some very focused initiatives to make sure that we are leading the way there like you would think a market leader would do. And you see a lot of that playing out at FMT. On the solutions side, this is not a ubiquitous solution, but you see it playing out in fire. We've talked about the automation there. It's a decent part of the growth and the strong numbers that they've put up. That's a slower to change industry, but it's starting to take and get some real traction there. And that's all about digital functionality and automation, helping solve this problem at crew size. We talked about our water businesses. At the core, all that hardware ultimately presents information that is shown digitally and is now more seamless and more integrated than it was before. So it's just -- I wanted to make sure that people appreciate that part of becoming a larger company and a little bit more thematic organization, you start to get benefits in this way. And we're participating in our own IDEX-like way. Q – Rob Wertheimer: Perfect. Thank you.

Thank you. There are no further questions at this time. I would like to hand the floor back over to Eric Ashleman for any closing comments.

Thanks so much. Thanks for everybody for joining today. I really appreciate the questions and the interest. And look, I think the bottom line here, still a choppy and uncertain world, no doubt. But we're in a good spot at IDEX. We're not out of the woods yet at HST, but it's really great to see the strong year-over-year orders comp, a modest backlog build, and the sequential orders uptick to the high point. We'll have to wait a bit, see how that recovery plays out from here. But look, I think we've strengthened our portfolio a lot as we prepare ourselves for a cycle of sunnier days ahead, no doubt, through the acquisitions. And Mott here at the end is a really good indicator of that. Our two other segments are doing really, really well with some nice pockets of growth. And execution, as always, at IDEX is strong across the board. We think the second half of the decade, which, by the way, is only two months away from starting, it's going to be a tremendous period of value creation overall for IDEX. And I really look forward to talking with you about it in the quarters to come. Thanks. Have a great day.

Thank you.

Thank you.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.